FDA approves first drug for reducing the risk of sexually acquired HIV infection

7 July 2022

This article from July 16, 2012 announces the U.S. Food and Drug Administration’s approval of Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners.

Featured Resources

External Link

How Men Influence Young Women Taking PrEP: Perspectives from young women, male partners, and male peers in Siaya county, Western Kenya

This article from BMC Women’s Health describes the results of a study exploring the views of young women, male partners, and male peers of young women in Siaya County, Western Kenya, to illustrate how men influence, and can support, young women in using PrEP.

External Link

Questioning Risk Compensation: Pre-exposure prophylaxis (PrEP) and sexually transmitted infections among men who have sex with men, capital region of Denmark, 2019 to 2022

This article from Eurosurveillance describes the results of a study comparing rates for chlamydia, gonorrhoea and syphilis before and after PrEP initiation in gay and bisexual men who have sex with men in Denmark.

External Link

Uptake and Challenges with Daily Oral Pre-exposure Prophylaxis among Men who Have Sex with Men and Transgender Women, Suburban Yangon, Myanmar

This article from International Health describes PrEP uptake and 12 month retention amongst gay and bisexual men who have sex with men and transgender women in Myanmar during the covid-19 pandemic and a political crisis and includes insights into user motivations for uptake and continuation.

PrEP for Pregnant and Breastfeeding People: Advocacy, Policy, and Programmatic Tools

Evidence shows that offering PrEP is a safe and effective HIV prevention strategy for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of PrEP to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that people have an increased need for HIV…

Document

Private Sector Market Assessment: Eswatini

This market assessment explores the opportunities and barriers to leveraging private sector channels to expand access to new and existing pre-exposure prophylaxis (PrEP) methods, including oral PrEP, the dapivirine vaginal ring (PrEP ring), and long acting cabotegravir (CAB PrEP) in Eswatini.

Document

CATALYST Interim Learnings (May-November 2023)

In this first interim analysis, the MOSAIC team provides key learnings from preparing for the delivery of PrEP choice, a summary of challenges experienced in implementing the enhanced service delivery model and the solutions introduced, programmatic considerations for countries preparing to introduce new PrEP methods, and a list of publicly accessible tools and resources used…

External Link

Estimating the Costs and Perceived Benefits of Oral Pre-exposure Prophylaxis (PrEP) Delivery in Ten Counties of Kenya: A costing and a contingent valuation study

This article from Frontiers in Reproductive Health describes the results of a study to calculate the actual costs of oral PrEP scale-up in ten counties in Kenya, including a comparison of service delivery models across regions. In addition, the study looked at factors that indicate why some individuals place a greater value on PrEP than…

External Link

HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women

This article from the Journal of the American Medical Association describes the results of a pooled analysis to measure HIV incidence among cisgender women with different adherence trajectories to oral PrEP with TDF/FTC.

Document

HIV Pre & Post-Exposure Prophylaxis Guidelines in Zambia, December 2023

This document aims to provide Ministry of Health guidance on the implementation of PEP and PrEP to prevent HIV transmission and improve overall health outcomes. This comprehensive approach reflects the commitment of all involved in combating HIV and enhancing public health.

External Link

ICAP PrEP Package for Providers: PrEParing for Choice

ICAP’s PrEP Package for Providers: PrEParing for Choice was developed by ICAP at Columbia University to promote the introduction and implementation of multiple PrEP products. The material is designed to capacitate health care teams with the knowledge and skills to counsel clients about PrEP and PrEP options, conduct effective PrEP initiation visits, and monitor and…